Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Protein array-based companion diagnostics in precision medicine

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Complete invasive diagnosis of patients with ischemia with nonobstructive coronary arteries: why it matters

    Research output: Contribution to journalEditorialResearchpeer-review

  2. From next-generation sequencing to targeted treatment of non-acquired epilepsies

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lessons learned from the implementation of non-invasive fetal RHD screening

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Complement component 3 and its activation split-products in saliva associate with periodontitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Peptidylarginine Deiminase 2 Gene Polymorphisms in Subjects with Periodontitis Predispose to Rheumatoid Arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Transcriptomic Fingerprint of Bacterial Infection in Lower Extremity Ulcers

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab: A Case Series

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Thomas B G Poulsen
  • Azra Karamehmedovic
  • Christopher Aboo
  • Malene Møller Jørgensen
  • Xiaobo Yu
  • Xiangdong Fang
  • Jonathan M Blackburn
  • Claus H Nielsen
  • Tue W Kragstrup
  • Allan Stensballe
View graph of relations

INTRODUCTION: The development of companion diagnostics (CDx) will increase efficacy and cost-benefit markedly, compared to the currently prevailing trial-and-error approach for treatment. Recent improvements in high-throughput protein technology have resulted in large amounts of predictive biomarkers that are potentially useful components of future CDx assays. Current high multiplex protein arrays are suitable for discovery-based approaches, while low-density and more simple arrays are suitable for use in point-of-care facilities.

AREA COVERED: This review discusses the technical platforms available for protein array focused CDx, explains the technical details of the platforms and provide examples of clinical use, ranging from multiplex arrays to low-density clinically applicable arrays. We thereafter highlight recent predictive biomarkers within different disease areas, such as oncology and autoimmune diseases. Lastly, we discuss some of the challenges connected to the implementation of CDx assays as point-of-care tests.

EXPERT OPINION: Recent advances in the field of protein arrays have enabled high-density arrays permitting large biomarker discovery studies, which are beneficial for future CDx assays. The density of protein arrays range from a single protein to proteome-wide arrays, allowing the discovery of protein signatures that may correlate with drug response. Protein arrays will undoubtedly play a key role in future CDx assays.

Original languageEnglish
JournalExpert Review of Molecular Diagnostics
Volume20
Issue number12
Pages (from-to)1183-1198
Number of pages16
ISSN1473-7159
DOIs
Publication statusPublished - Dec 2020

    Research areas

  • Autoimmune diseases, companion diagnostics, cdx, oncology, point-of-care, precision medicine, predictive biomarkers, protein array

ID: 61864055